Loading...
•
Dec 31, 2025
CG Oncology Inc Q4 2025 Earnings Report
CG Oncology Inc reported its Q4 2025 results with increased operating expenses and a wider net loss while maintaining a strong cash position.
Key Takeaways
For Q4 2025, CG Oncology reported total revenue of $1159000 and a net loss of $41300000 as operating expenses increased year-over-year driven by higher R&D and G&A costs. The company ended the year with $742155000 in cash, cash equivalents and marketable securities.
Total revenue was $1159000 in Q4 2025, driven by collaboration revenue.
Net loss widened to $41300000 compared to $31800000 in Q4 2024.
R&D expenses increased to $30000000 due to higher clinical and CMC costs.
Cash, cash equivalents and marketable securities totaled $742155000 at December 31, 2025.
Revenue by Segment
Forward Guidance
The company expects key Phase 3 and Phase 2 clinical data readouts in the first half of 2026 and anticipates sufficient cash runway into the first half of 2029.
Positive Outlook
- Phase 3 PIVOT-006 topline data expected in 1H 2026.
- CORE-008 Cohort CX combination data expected in 1H 2026.
- Planned completion of BLA submission in 2026.
- Durability data updates from multiple cohorts anticipated in 2026.
- Cash runway expected to fund operations into the first half of 2029.
Challenges Ahead
- Ongoing net losses expected as development continues.
- Increasing R&D and G&A expenses year-over-year.
- Regulatory approvals are not yet secured.
- Clinical outcomes remain subject to risk and uncertainty.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...